At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
- An Acupuncture Study for Historically Under-Represented Cancer Survivors with Chronic Musculoskeletal Pain
Full Title Researching the Implementation of Acupuncture for Chronic Musculoskeletal Pain in Diverse Underserved Cancer Survivors (ReIMAGINE)
Purpose
Many survivors of cancer develop joint and muscle pain after receiving treatments for their cancer.
Research has shown that acupuncture can help with pain, but prior studies did not include many people from certain backgrounds. Researchers are doing this study to see if acupuncture could also work for people who were not well-represented in previous research.
If you join this study, you will be randomly assigned to get acupuncture over 10 weeks or your usual care. You will fill out questionnaires about your symptoms, quality of life, and use of pain treatments. If you are in the usual care group, you can receive 10 vouchers for acupuncture after the study is over.
Who Can Join
To join this study, there are a few conditions. You must:
- Have completed treatment for cancer at least 1 month before starting the study.
- Be experiencing moderate to severe joint or muscle pain for 1 month or more.
- Not have previously received acupuncture for pain in the past 3 months.
Researchers will also ask other questions to see if you are able to join this study.
Contact
For more information, please email [email protected].
Protocol
24-305Disease Status
Relapsed or RefractoryInvestigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT06814977ClinicalTrials.gov
-
The purpose of this study is to find the best dose of ABBV-383 to treat AL amyloidosis. The people in this study have AL amyloidosis that came back or does not get better with treatment.
-
Researchers are assessing a drug called rQNestin34.5v.2, for people with brain cancer that came back after treatment. The people in this study have a type of brain cancer called a glioma.
-
CAR T-cell therapies are a form of immunotherapy where some of a patient's T cells are removed, modified in the laboratory to recognize a protein on cancer cells, multiplied, and returned to the patient to provoke an immune attack against cancer. Sometimes the new T cells cause side effects related to the immune system's response to the treatment.
-
Researchers want to see how well revumenib works when given with chemotherapy to treat infant leukemia. The children in this study have acute leukemia that came back or keeps growing even after treatment. The leukemia has a gene rearrangement (genetic change) called KMT2A-R.
-
Researchers want to see if adding radiation therapy to standard medical treatments works better than standard therapies alone in people with kidney cancer. The standard therapies include:
-
In this study, researchers are assessing the safety of the drug lurbinectedin in young people with solid tumors. In the first part, they will find the highest dose of lurbinectedin to use safely in children with solid tumors. If your child joins, this is the part of the study they will be in.
-
Researchers want to find the best dose of GI-102 for treating advanced sarcoma. The people in this study have sarcoma that has spread.
-
Researchers are comparing two treatments for people with non-muscle invasive bladder cancer. If you take part in this study, you will be randomly assigned to get either:
-
This study is evaluating the safety and effectiveness of combination chemotherapy, surgery, and radiation therapy in children and young adults with newly diagnosed stage II-IV diffuse anaplastic Wilms' tumors (DAWT) or favorable histology Wilms' tumors (FHWT) that have come back (relapsed).